The group held the 7th meeting of the 11th board of directors and the 7th meeting of the 10th board of supervisors to review and approve relevant reports and proposals

Release time:


On April 16, Jiang Xiaomeng, chairman of the group company, presided over the 7th meeting of the 11th board of directors of the company, deliberated and passed 17 related reports and proposals, including the report of the board of directors in 2021, the business report of the general manager in 2021, the annual report in 2021, the financial final accounts report in 2021, and the profit distribution plan in 2021.

    4Month16On the same day, Jiang Xiaomeng, chairman of the group company, presided over the 11th board of directors of the company.7Meeting, considered and adopted2021Annual Board Report,2021Annual General Manager Business Report,2021Annual Report,2021Annual financial statements,2021Annual profit distribution plan, etc.17related reports and motions.

The general manager pointed out in the report,2021The year is the first year of the national "14th Five-Year Plan".,According to the company's five-year development plan and the annual business plan approved by the board of directors, the management team, focusing on the general policy of "following the law, keeping the new, changing and innovating, and continuously improving", calmly responded to the new coronary pneumonia epidemic, the ups and downs of raw material prices, production restrictions and electricity restrictions and many other challenges, and better completed the work objectives set at the beginning of the year. As2021At the end of the year, the total assets of the company were70.24Billion yuan, year-on-year growth10.74%, the net assets attributable to shareholders of the listed company are52.07Billion yuan, year-on-year growth17.39%. Annual operating income38.05Billion yuan, year-on-year growth17.17%, to achieve net profit attributable to shareholders9.24Billion yuan, year-on-year growth58.12%The operating performance has reached the best level in history.

    2021In 2010, the pharmaceutical company made progress in a number of technical improvements and engineering construction, and the annual production capacity of the Jinxi production base of Peak Pharmaceuticals20The construction of the 100 million solid preparations (internationalization) project is progressing in an orderly manner. At present, the civil engineering, equipment installation and commissioning of the project have been basically completed, and the project acceptance and talent are underway.cGMPPreparatory work for the application for certification; New North Card and Jianfeng North Card continue to implement comprehensive technological transformation, and plan to upgrade on the basis of existing pesticides and pharmaceutical intermediates to build a comprehensive R & D and production base for APIs, pharmaceutical intermediates and pesticides, and actively promote the industrial upgrading strategy of the integration of APIs and preparations in the pharmaceutical sector of the company. Spike Pharmaceuticals and its subsidiaries further increased their investment in research and development, completing moxifloxacin hydrochloride eye drops, lenvatinib mesylate capsules, valsartan amlodipine tablets, esomeprazole magnesium enteric dry suspension4The registration of a drug. Peak pharmaceutical products won the bid for the first time in the national drug centralized procurement, olopatadine hydrochloride eye drops won the bid for the fourth batch of national drug centralized procurement, which is conducive to the market promotion of the product, sales have been greatly improved.

     On the same day, the company also held the 10th board of supervisors.7Meeting, considered and adopted the company.2021Annual Supervisory Board Report, etc.7related reports and motions.